Retinoblastoma - Healing Genes


Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase 2


Seattle Children’s Hospital researchers are recruiting participants for a study on how well a gene-modified immunotherapy can shrink relapsed tumors of these solid cancers:

  • Pediatric Solid Tumor
  • Germ Cell Tumor
  • Retinoblastoma
  • Hepatoblastoma
  • Wilms Tumor
  • Rhabdoid Tumor
  • Carcinoma
  • Osteosarcoma
  • Ewing Sarcoma
  • Rhabdomyosarcoma
  • Synovial Sarcoma
  • Clear Cell Sarcoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Desmoplastic Small Round Cell Tumor
  • Soft Tissue Sarcoma
  • Neuroblastoma

The investigational therapy will withdraw 2 types of white blood cells (T-cells) from the patient and, utilizing gene editing, the T-cells will be taught to target their tumors. The genetic modification will also allow for the T-cells to be turned off if needed, should an adverse reaction occur. Once prepared in the lab, the altered T-cells will be returned by IV and their growth encouraged with additional therapy. Recovery for 1 to 2 weeks in the hospital is expected, then participants will be followed for ~2 years.


  • Be 1 Year to 26 Years of age
  • Have Life expectancy ≥ 8 weeks
  • Not be pregnant or breastfeeding
  • Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment
  • Meet screening requirements regarding the status of their cancer and overall health, past treatments, and their current medications


  1. Prescreening tests to confirm eligibility of the patient to participate
  2. T-cells will be drawn via IV and a central line, or IV catheter, may be placed in the patient’s chest
  3. The patient will receive no treatment while the T-cells are gene-modified in a lab
  4. The patient’s changed cells will be re-administered
  5. Follow up will continue for up to 84 days


The study site is at the Seattle Children’s Hospital in Seattle, WA. Map.

Contact: Katie Albert, MD  |  206-987-2106  |  [email protected]



Seattle Children’s Hospital

Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader